» Articles » PMID: 38402337

MiR-135b Aggravates Fusobacterium Nucleatum-Induced Cisplatin Resistance in Colorectal Cancer by Targeting KLF13

Overview
Journal J Microbiol
Specialty Microbiology
Date 2024 Feb 24
PMID 38402337
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin resistance is the main cause of colorectal cancer (CRC) treatment failure, and the cause has been reported to be related to Fusobacterium nucleatum (Fn) infection. In this study, we explored the role of Fn in regulating cisplatin resistance of CRC cells and its underlying mechanism involved. The mRNA and protein expressions were examined by qRT-PCR and western blot. Cell proliferation and cell apoptosis were assessed using CCK8 and flow cytometry assays, respectively. Dual-luciferase reporter gene assay was adopted to analyze the molecular interactions. Herein, our results revealed that Fn abundance and miR-135b expression were markedly elevated in CRC tissues, with a favorable association between the two. Moreover, Fn infection could increase miR-135b expression via a concentration-dependent manner, and it also enhanced cell proliferation but reduced apoptosis and cisplatin sensitivity by upregulating miR-135b. Moreover, KLF13 was proved as a downstream target of miR-135b, of which overexpression greatly diminished the promoting effect of miR-135b or Fn-mediated cisplatin resistance in CRC cells. In addition, it was observed that upstream 2.5 kb fragment of miR-135b promoter could be interacted by β-catenin/TCF4 complex, which was proved as an effector signaling of Fn. LF3, a blocker of β-catenin/TCF4 complex, was confirmed to diminish the promoting role of Fn on miR-135b expression. Thus, it could be concluded that Fn activated miR-135b expression through TCF4/β-catenin complex, thereby inhibiting KLF13 expression and promoting cisplatin resistance in CRC.

Citing Articles

: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer.

Luo M, Li Q, Gu Q, Zhang C Am J Cancer Res. 2024; 14(8):3962-3975.

PMID: 39267665 PMC: 11387864. DOI: 10.62347/MYZA2640.


Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies.

Shi Z, Li Z, Zhang M J Transl Med. 2024; 22(1):837.

PMID: 39261861 PMC: 11391643. DOI: 10.1186/s12967-024-05640-7.


Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer.

Hamamah S, Lobiuc A, Covasa M Int J Mol Sci. 2024; 25(16).

PMID: 39201713 PMC: 11354872. DOI: 10.3390/ijms25169026.


Identification of Penexanthone A as a Novel Chemosensitizer to Induce Ferroptosis by Targeting Nrf2 in Human Colorectal Cancer Cells.

Zhao G, Liu Y, Wei X, Yang C, Lu J, Yan S Mar Drugs. 2024; 22(8).

PMID: 39195474 PMC: 11355289. DOI: 10.3390/md22080357.

References
1.
Arthur J, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis J, Fan T . Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338(6103):120-3. PMC: 3645302. DOI: 10.1126/science.1224820. View

2.
Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R . The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. Int J Mol Sci. 2018; 19(12). PMC: 6321452. DOI: 10.3390/ijms19123711. View

3.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

4.
Chen S, Zhang L, Li M, Zhang Y, Sun M, Wang L . Fusobacterium nucleatum reduces METTL3-mediated mA modification and contributes to colorectal cancer metastasis. Nat Commun. 2022; 13(1):1248. PMC: 8913623. DOI: 10.1038/s41467-022-28913-5. View

5.
Cheng Y, Ling Z, Li L . The Intestinal Microbiota and Colorectal Cancer. Front Immunol. 2020; 11:615056. PMC: 7734048. DOI: 10.3389/fimmu.2020.615056. View